B7-33 (Modified Relaxin-2 Analog)

Price range: $58.00 through $200.00

Product Classification

Classified as an RXFP1 pathway peptide analog

Description

B7-33 is a single-chain relaxin analog designed to activate RXFP1 signaling with reduced mitogenic activity compared to native relaxin.
Research focuses on anti-fibrotic mechanisms, extracellular matrix remodeling, and cardiovascular pathways

Specifications

  • Molecular Type: Relaxin-2 analog
  • Mechanism: RXFP1-mediated anti-fibrotic and vasodilatory signaling

Research Notes

  • - Anti-Fibrotic: preclinical models report reduced collagen deposition and fibrosis.
  • - ECM Remodeling: influences matrix metalloproteinases and stromal remodeling
  • - Cardiovascular: evaluated in heart failure and pulmonary hypertension models
  • Mitogenic Sparing: analog design minimizes proliferative signaling of relaxin.
Regulatory Statement

For research use only. Not for human or animal consumption.

Not evaluated by FDA. Not intended to diagnose, treat, cure, or prevent disease

SKU: N/A Category:

Additional information

Strength

10mg, 2mg

Reviews

There are no reviews yet.

Be the first to review “B7-33 (Modified Relaxin-2 Analog)”

Your email address will not be published. Required fields are marked *